In 1986, the ulcer drug Tagamet from Smith, Kline and French (now GSK) emerged as the first blockbusters, generating more than $1 billion in annual revenue. Fast-forward to 2021, and the COVID-19 vaccine from Pfizer and BioNTech generated close to $60 billion in cumulative revenue. That same year, AbbVie’s Humira (adalimumab) eclipsed $20 billion in sales…